AKSY Stock Overview
Aksys Ltd. provides hemodialysis products and services for patients suffering from end-stage renal disease, known as chronic kidney failure.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Aksys Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -100.00% |
| 5 Year Change | -90.00% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| AKSY | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | 1.4% | 1.2% |
| 1Y | n/a | -0.7% | 24.7% |
Return vs Industry: Insufficient data to determine how AKSY performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how AKSY performed against the US Market.
Price Volatility
| AKSY volatility | |
|---|---|
| AKSY Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AKSY's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine AKSY's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | n/a | n/a | n/a |
Aksys Ltd. provides hemodialysis products and services for patients suffering from end-stage renal disease, known as chronic kidney failure. The company offers an automated personal hemodialysis system, known as the Aksys PHD, a Personal Hemodialysis System (PHD System), which is designed to enable patients to perform frequent hemodialysis at alternate sites, such as their own homes. The PHD System is designed to monitor, during the treatment, various vital statistics, including the patient’s blood flow rate, the amount of water removed from the patient, the length of the treatment session, and other parameters.
Aksys Ltd. Fundamentals Summary
| AKSY fundamental statistics | |
|---|---|
| Market cap | US$32.00 |
| Earnings (TTM) | -US$54.81m |
| Revenue (TTM) | US$2.60m |
0.0x
P/S Ratio0.0x
P/E RatioIs AKSY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AKSY income statement (TTM) | |
|---|---|
| Revenue | US$2.60m |
| Cost of Revenue | US$7.21m |
| Gross Profit | -US$4.61m |
| Other Expenses | US$50.20m |
| Earnings | -US$54.81m |
Last Reported Earnings
Sep 30, 2006
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did AKSY perform over the long term?
See historical performance and comparison